Invention Grant
- Patent Title: Monoclonal and humanized antibodies to a cancer glycopeptide
-
Application No.: US16478833Application Date: 2017-01-18
-
Publication No.: US11673966B2Publication Date: 2023-06-13
- Inventor: Dapeng Zhou , Patrick Hwu
- Applicant: NanoCruise Pharmaceutical Ltd. , Board of Regents of The University of Texas System
- Applicant Address: CN TX Jiangsu
- Assignee: NanoCruise Pharmaceutical Ltd.,Board of Regents of The University of Texas System
- Current Assignee: NanoCruise Pharmaceutical Ltd.,Board of Regents of The University of Texas System
- Current Assignee Address: CN Jiangsu; US TX Austin
- Agency: Reising Ethington P.C.
- International Application: PCT/CN2017/071546 2017.01.18
- International Announcement: WO2018/132976A 2018.07.26
- Date entered country: 2019-07-17
- Main IPC: C07K16/30
- IPC: C07K16/30 ; A61P35/00 ; C07K16/46 ; A61K39/00
Abstract:
The present invention discloses a mouse-human chimeric antibody preferably recognizes the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and the encoding sequences, wherein the monoclonal antibody having a light chain and a heavy chain. Moreover, the present invention provides humanized light and heavy chains, and the encoding sequences. The results of paired expression show that humanized antibodies also recognize the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and show the same specificity as the parental antibody.
Information query
